Project Vaccinate

STUART, FL – (GLOBE NEWSWIRE) – February 17, 2021 – The iRemedy Healthcare Companies, Inc. (“iRemedy” or “the Company”), pioneer of the iRemedy™ medical supply marketplace, today announced that the Company has arranged for the procurement of an additional 500 million low-dead space syringes and needles in association with iRemedy’s “Project Vaccinate” initiative, created to support global demand for FDA-approved injection devices required for administration of COVID-19 vaccinations.

STUART, FL – (GLOBE NEWSWIRE) – February 17, 2021 – The iRemedy Healthcare Companies, Inc. (“iRemedy” or “the Company”), pioneer of the iRemedy™ medical supply marketplace, today announced that in association with the Company’s effort to procure and deliver one billion FDA-approved hypodermic needles and syringes in support of COVID-19 vaccination programs worldwide, over 130 million units have been delivered to customers since announcing its program in November 2020.

STUART, FL – November 18, 2020 – The iRemedy Healthcare Companies, Inc. (“iRemedy” or “the Company”), pioneer of the iRemedy™ medical supply marketplace, today announced that in anticipation of COVID-19 vaccines becoming available soon, the Company has procured factory capacity for production of over one billion, FDA-approved hypodermic needles and syringes that will be required for administration of vaccinations to the public on a global basis.